title: [Effect of sarpogrelate in enteral feeding of patients with gastroesophageal reflux (GER)].
abstract: OBJECTIVE
  Enteral feeding of patients who are unable to eat or drink because of neurological disorders finally undergo percutaneous endoscopic gastrostomy (PEG) or nasogastric tube feeding. Their most common serious complication is aspiration pneumonia. Our objectives were to evaluate the effect of sarpogrelate (a 5-HT2A receptor blocker) on gastroesophageal reflux (GER) in these patients.
  
  
  METHODS
  This study was performed in 5 elderly patients, aged 70-87 years with neurological disorders (stroke 4, post herpes encephalitis 1), on PEG or nasogastric feeding for 5 weeks-1 year. A 48-hour esophageal pH study was performed using the Degitrapper pH400 (Medtronic Co.). The pH monitor catheter was passed into the esophagus transnasally and positioned with the pH electrode 5cm above the lower esophageal sphincter. During the first 24 hours drug no drug was given, and during the next 24 hours we gave 100mg sarpogrelate 3 times. We analyzed the frequency of acid reflux (when the pH in the esophagus become less than 4.0 for more than 5 seconds, we defined this is 1 episode of acid reflux), frequency of acid reflux and mean pH values between drug-on and drug-off periods. An upright position was maintained for two hours after each meal.
  
  
  RESULTS
  When the results of pH monitoring during two half days (from 7 pm to 7 am: 12 hours) was compared between drug-on term and drug-off term, mean pH value was statistically elevated from 6.0 +/- 0.2 (drug-off) to 6.5 +/- 0.4 (drug-on) (mean +/- SD, p< 0.05). Frequency and the total time of acid reflex showed no difference between the two periods.
  
  
  CONCLUSIONS
  Treatment with sarpogrelate might be effective in patients with GER by blocking activated serotonin receptor in the gastrointestinal system.
authors.affiliation: Department of Neurology, Hematology & Rheumatology, Shimane University Hospital.
authors.forename: Yukie
authors.initials: Y
authors.lastname: Satou
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Oguro
authors.forename: Yo
authors.initials: Y
authors.lastname: Murakami
authors.forename: Satoshi
authors.initials: S
authors.lastname: Abe
authors.forename: Shuhei
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Shotai
authors.initials: S
authors.lastname: Kobayashi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004750:Enteral Nutrition; D004947:Esophagus / Q000503:physiopathology*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D005774:Gastrostomy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007441:Intubation, Gastrointestinal; D018670:Monitoring, Ambulatory; D012702:Serotonin Antagonists / Q000008:administration & dosage*; D013386:Succinates / Q000008:administration & dosage*
chemical_list: D012702:Serotonin Antagonists; D013386:Succinates; C064294:sarpogrelate